MAOA基因型、性別及抽菸為精神分裂症病人在Olanzapine治療反應之預測因子

Monoamine Oxidase A Polymorphism, Gender, and Smoking as Predictors for Treatment Respose in Olanzapine-treated patients with Schizophrenia

目的：本研究旨在探討以olanzapine 治療精神分裂症，其治療效果與MAOA 基因型的 相關性。方法：在三個月的治療期間，以olanzapine 治療60 位精神分症狀病人；治療效果 以活性與負性症狀量表評估。結果：對於攻擊症狀，短型的MAOA 治療效果較佳；女性對 olanzapine 有較好的治療反應；沒有抽菸的病人，其攻擊面向對olanzapine 有效好的反應。 結論：研究結果顯示，當以olanzapine 治療精神分裂症時，MAOA 基因型、女性性別、及 病人沒有抽菸對於治療反應是有用的預測因子。

Objective: The aim of this study was to explore the treatment effect of olanzapine on the polymorphisms of monoamine oxidase A (MAOA) in schizophrenia. Method: During a 3-month period, 60 patients with schizophrenia were administered olanzapine. Treatment response was assessed by checking for improvement in symptoms as measured on the Positive and Negative Syndrome Scale (PANSS). Results: The short form of MAOA demonstrated a better drug response in the dimension of aggression. Female patients had a better response to olanzapine. Patients who did not smoke had a better response to olanzapine in the dimension of aggression. Conclusion: The results of this study suggest that polymorphisms of MAOA, gender, and cigarette smoking may be three useful response predictors in schizophrenic patients who were treated with olanzapine.